ARQT
Arcutis Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$25.87
+1.93%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11Sep 16Sep 21
Key dataSep 21, 2026
Open$25.57
From 52W high−17.08%
Volume63163.00
Market cap$3.25B
P/E (TTM)117.2x
P/S (TTM)7.0x
Div yield—
Key dataSep 21, 2026
Open
$25.57
From 52W high
−17.08%
Volume
63163.00
Market cap
$3.25B
ValuationView details →
P/E (Fwd)
32.1x
EV/EBITDA
70.9x
P/E (TTM)
117.2x
RSI (14)
53.6
MomentumView details →
1D Return
+1.93%
YTD Return
−12.00%
SummaryUpdated Jun 1, 2026
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a commercial-stage biopharmaceutical company founded in 2016 and headquartered in Westlake Village, California. The company went public in January 2020 and focuses on developing and commercializing innovative treatments for dermatological diseases. Arcutis has successfully transitioned from a clinical-stage company to a commercial enterprise, with its flagship product ZORYVE generating significant revenue growth since its initial launch for plaque psoriasis in 2022.
Similar companies
Latest newsMore news →
Arcutis Biotherapeutics (ARQT) shares rose 11.2% in the previous trading session on higher-than-average volume.4d agoDow Jones Indices announced changes to the S&P 600 index, adding ten companies and removing ten others, effective before the open on September 21, 2026, as part of the quarterly rebalance.17d ago